Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1989 1
2007 1
2009 1
2010 2
2011 4
2012 9
2013 9
2014 13
2015 20
2016 20
2017 17
2018 11
2019 13
2020 20
2021 21
2022 21
2023 14
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Stratigos AJ, et al. Lancet Oncol. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000246 Free article. Clinical Trial.
BACKGROUND: Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. ...Here, we present the primary analysis data of cemiplimab in patients with locally …
BACKGROUND: Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma …
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
Villani A, Potestio L, Fabbrocini G, Scalvenzi M. Villani A, et al. Adv Ther. 2022 Mar;39(3):1164-1178. doi: 10.1007/s12325-022-02044-1. Epub 2022 Jan 28. Adv Ther. 2022. PMID: 35089534 Free PMC article. Review.
Objective of this review is to analyze and discuss the novel therapies for advanced basal cell carcinoma and squamous cell carcinoma to obtain a sharper perspective of the available treatment options....
Objective of this review is to analyze and discuss the novel therapies for advanced basal cell carcinoma and squ …
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Sekulic A, et al. N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713. N Engl J Med. 2012. PMID: 22670903 Free PMC article. Clinical Trial.
A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma. METHODS: In this multicenter, international, two-cohort, nonrand …
A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate amo …
Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
Dummer R, Ascierto PA, Basset-Seguin N, Dréno B, Garbe C, Gutzmer R, Hauschild A, Krattinger R, Lear JT, Malvehy J, Schadendorf D, Grob JJ. Dummer R, et al. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1944-1956. doi: 10.1111/jdv.16230. Epub 2020 Mar 4. J Eur Acad Dermatol Venereol. 2020. PMID: 31990414 Free article. Review.
Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the treatment of advanced basal cell carcinoma (BCC). Until recently, vismodegib was the only targeted treatment available for patients with locally advanced BCC (laBCC) in ca …
Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the treatment of advanced basal cell ca …
Vismodegib.
Dlugosz A, Agrawal S, Kirkpatrick P. Dlugosz A, et al. Nat Rev Drug Discov. 2012 Jun 1;11(6):437-8. doi: 10.1038/nrd3753. Nat Rev Drug Discov. 2012. PMID: 22653209 Free PMC article.
Given the absence of previously defined effective drug therapy for this disease, approval was granted based primarily on outcome of a non-randomized parallel cohort phase II study of 99 patients with advanced basal cell carcinoma, with a primary …
Given the absence of previously defined effective drug therapy for this disease, approval was granted based primarily on outcome of a non- …
Vismodegib.
Rudin CM. Rudin CM. Clin Cancer Res. 2012 Jun 15;18(12):3218-22. doi: 10.1158/1078-0432.CCR-12-0568. Epub 2012 Jun 7. Clin Cancer Res. 2012. PMID: 22679179 Free PMC article. Clinical Trial.
Given the absence of previously defined effective drug therapy for this disease, approval was granted primarily on the basis of outcome of a nonrandomized parallel cohort phase II study of 99 patients with advanced basal cell carcinoma, with a primary …
Given the absence of previously defined effective drug therapy for this disease, approval was granted primarily on the basis of outcome of a …
Cancer interception.
Blackburn EH. Blackburn EH. Cancer Prev Res (Phila). 2011 Jun;4(6):787-92. doi: 10.1158/1940-6207.CAPR-11-0195. Cancer Prev Res (Phila). 2011. PMID: 21636545
For example, hedgehog pathway studies of mutations in the patched homolog 1 (PTCH1) gene, which constitutively activates Smoothened (SMO), led to development of an oral SMO inhibitor active in advanced basal cell carcinoma and which, in very high-risk …
For example, hedgehog pathway studies of mutations in the patched homolog 1 (PTCH1) gene, which constitutively activates Smoothened (SMO), l …
The Landmark Series: Non-melanoma Skin Cancers.
Lee AY, Berman RS. Lee AY, et al. Ann Surg Oncol. 2020 Jan;27(1):22-27. doi: 10.1245/s10434-019-07831-9. Epub 2019 Sep 23. Ann Surg Oncol. 2020. PMID: 31549317 Review.
Until recently, there were no effective systemic therapies for patients with advanced disease. This review will focus on the landmark clinical trials that led to Food and Drug Administration (FDA) approval of Vismodegib for advanced basal cell carci …
Until recently, there were no effective systemic therapies for patients with advanced disease. This review will focus on the landmark cli …
Management of high-risk and advanced basal cell carcinoma.
Puig S, Berrocal A. Puig S, et al. Clin Transl Oncol. 2015 Jul;17(7):497-503. doi: 10.1007/s12094-014-1272-9. Epub 2015 Feb 3. Clin Transl Oncol. 2015. PMID: 25643667 Free PMC article. Review.
Despite that basal cell carcinoma (BCC) is curative in the vast majority of cases, some patients are at high risk of recurrence and, in a few patients, lesions can progress to a point unsuitable for local therapy and prognosis is quite poor. The aim of the present work is to revi …
Despite that basal cell carcinoma (BCC) is curative in the vast majority of cases, some patients are at high risk of recurrence and, in a fe …
176 results